UNSPSC 51386612: Hydrocortisone/sulfur/zinc oxide

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE200. This VA Drug Class (DE200) classifies this compound as belonging to the group ANTI-INFLAMMATORY, TOPICAL.

UNSPSC 51386612 Hydrocortisone/sulfur/zinc oxide is a Commodity code, but the recent state and local solicitations tagged under it diverge sharply from its nominal scope and instead reflect procurement of emergency response pharmaceuticals, controlled-substance antagonists, and generic multi-source medications through state and cooperative purchasing vehicles. State and local governments are not currently soliciting hydrocortisone/sulfur/zinc oxide topical combinations under this code; instead, they are buying naloxone (an opioid antagonist), safe drug deactivation systems, and broad generic pharmaceutical inventory through cooperative and direct-to-manufacturer models. The issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, serving Minnesota and Oregon). This pattern suggests a significant tag mismatch between the UNSPSC code designation and the actual goods being procured.

Recent activity spans Florida, Texas, Minnesota, and Oregon. Seminole County issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023 (noting a date inconsistency in the source). Texas HHS issued RFI HHS0017013 on April 3, 2026, to solicit vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program. MMCAP, administered by Minnesota's Department of Administration, issued an RFP on January 20, 2026 with a March 26, 2026 response deadline for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities, with contracts effective July 1, 2026. The code shows little relevant recent activity aligned with its stated pharmaceutical composition; state and local procurement professionals should verify code assignment and assess whether these opportunities match their actual product or service lines.